Wednesday, 30 June 2010
12:30
Expert discussion (by invitation only): The management of gastric cancer
Scientific Committee and selected experts
Level 1, Rooms 120-121
Session I: Selected abstracts I
Chairs: Mario Dicato, MD and Eric Van Cutsem, MD, PhD 15:00
Welcome and introduction
Mario Dicato, MD, Eric Van Cutsem, MD, PhD, and David J. Kerr, CBE, MA, MD, DSc, FRCP, FRCGP, FCanSci, FMedSci, ESMO President 15:05
Presentation of selected abstracts Highly accurate and validated RNA panels for early detection of colorectal cancer using small amount of blood samples
A. Rosenthal, et al., O-0027 Comprehensive DNA methylation profiling reveals three subgroups of colorectal cancer with distinct clinicopathological and molecular features
B. Lacopetta, et al., O-0001 Clinical outcomes in bevacizumab-treated patients with metastatic colorectal cancer: Results from ARIES observational cohort study and confirmation of BRiTE data on bevacizumab beyond progression
A. Cohn, et al., O-0002 Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of over 6000 patients in randomized phase II and III studies
J. Cassidy, et al., O-0003 Efficacy findings from the X-ACT trial of capecitabine vs 5-FU/LV as adjuvant therapy for patients with stage III colon cancer: No impact of age on disease-free survival or overall survival
C. Twelves, et al., O-0004 Efficacy findings from a randomised phase III trial of capecitabine + oxaliplatin vs bolus 5-FU/LV for stage III colon cancer (no16968): No impact of age on disease-free survival
D. Haller, et al., O-0005 Session II: Cancer of the pancreas and bile ducts
Chairs: Philippe Rougier, MD, PhD and Margaret A. Tempero, MD 16:00
Molecular pathogenesis and new therapeutic targets in pancreatic cancer
Nick R. Lemoine, MD, PhD, FRCPath, FMedSci 16:20
What to do in families with hereditary pancreatic cancer
Hans F. Vasen, MD, PhD 16:40
Diagnostic pitfalls in pancreatic cancer
Pascal Hammel, MD 17:00
Can a borderline resectable or non-resectable pancreatic cancer become resectable after a neoadjuvant treatment?
Francoise Mornex, MD, PhD 17:20
Presentation of selected abstracts Randomized phase III trial comparing FOLFIRINOX and gemcitabine as first line therapy for metastatic pancreatic adenocarcinoma: PRODIGE 4/ACCORD 11 trial
T. Conroy et al., Late breaking abstract Double-blind, placebo-controlled randomized phase III trial of aflibercept (A) plus gemcitabine (G) versus placebo (P) plus gemcitabine (G) in patients with metastatic pancreatic cancer: Final results
H. Riess, et al., O-0006 A phase III study comparing larotaxel to 5-FU (continuous intravenous 5-FU or capecitabine) in patients with advanced pancreatic cancer (APC) previously treated
with a gemcitabine containing regimen
E. Van Cutsem, et al., O-0007 17:50
Cases of pancreatic cancer: Adjuvant, locally advanced, and metastatic disease
Selected by Chris Verslype, MD, PhD 18:10
What is the optimal approach for patients with metastatic pancreatic cancer?
Volker Heinemann, MD, PhD 18:30
New treatment options on the horizon in pancreatic cancer and cholangiocarcinoma
Margaret A. Tempero, MD 18:50
Surgery for extrahepatic bile duct cancer
Jacques Belghiti, MD 19:10
Adjourn
CLOSED SESSION (by invitation only):
Parallel with Session II: Cancer of the pancreas and bile ducts 16:00
Strategy of national and international clinical trial groups in GI cancer
Level 1, Rooms 120-121 19:30
Adjourn closed session
Thursday, 1 July 2010
CLOSED SESSION (by invitation only):
Parallel with Session III: Meet the Expert concurrent presentations and Session IV: Cancer of the liver
8:00
How to go forward with translational research in GI cancer
Level 1, Rooms 131-132 Session III: Meet the Expert concurrent presentations 8:00
Carcinoma of unknown origin
Nicholas A. Pavlidis, MD, FACS
Level 1, Rooms 120-121 Anal cancer
Arnaud D. Roth, MD
Level 1, Rooms 122-123 Cholangiocarcinoma and gall bladder cancer
Jean-Luc Van Laethem, MD, PhD
Level 1, Rooms 124-125 GIST
John R. Zalcberg, MD, PhD
Level 1, Rooms 127-128 Reading or interpreting the medical literature
Daniel G. Haller, MD
Level 1, Rooms 129-130 Session IV: Cancer of the liver
Chairs: Michel Ducreux, MD, PhD and Josep M. Llovet, MD 8:50
Molecular changes occurring in pathogenesis of HCC
Josep M. Llovet, MD 9:10
Presentation of selected abstract
Phase III study of FOLFOX4 vs. doxorubicin in Asian patients with advanced HCC: Subgroup analyses according to baseline disease statusS
S. Qin, et al., O-0008 9:20
Treatment algorithm in HCC
Michel Ducreux, MD, PhD 9:40
New agents on the horizon in HCC
Jordan D. Berlin, MD 9:55
Keynote lecture 1: Biomarkers for GI cancer: Between hope and hype
comes histopathology!
Janusz A. Jankowski, MD, PhD,
FRCP, FACG 10:20
Break and Group 1 poster viewing (abstracts to be presented: poster discussion abstracts, clinical/basic esophageal,
clinical/basic liver, clinical/basic
pancreatic and abstracts selected as poster discussion) Session V: Rare tumors: Neuroendocrine tumors and gastrointestinal stromal tumors (GIST)
Chairs: Eduardo Diaz-Rubio, MD and John Zalcberg, MD, PhD 10:50
Is mutational analysis essential for the appropriate management of GIST?
John R. Zalcberg, MD, PhD 11:00
Clinical and pathological classification of NET
Irvin M. Modlin, MD, PhD, FRCS, FACSI, FACS 11:20
Presentation of selected abstract
90 Yttrium-DOTA-octreotate for
the treatment of advanced neuroendocrine tumours
C. Toumpanakis, et al., O-0010 11:30
Radionuclide treatment for NET
D. J. Kwekkeboom, MD 11:50
Presentation of selected abstract
Evidence of activity and clinical benefit with sunitinib in patients with pancreatic neuroendocrine tumors (NET)
E. Raymond, et al., O-0009 12.00
Everolimus versus placebo in patients with advanced pancreatic neuroendocrine tumors (pNET) (RADIANT-3)
J. Yao et al., Late Breaking abstract 12:15
Medical treatment of NET
Bertram Wiedenmann, MD 12:35
Session adjourns 12:45
Concurrent luncheon symposia begin 14:15
Concurrent luncheon symposia adjourn Session VI: Oesophageal cancer
Chairs: Bruce D. Minsky, MD and Robert Glynne-Jones, MD, FRCP 14:30
What is new in Barrett’s oesophagus?
Guido N. J. Tytgat, MD, PhD 14:50
Treatment of Barrett’s oesophagus
Prateek Sharma, MD 15:10
Pro – Con session on locally advanced oesophageal cancer Chemoradiotherapy alone is the standard
Laurent Bedenne, MD Chemoradiotherapy plus surgery
Michael Stahl, MD 15:40
Discussion and cases
Selected by Robert Glynne-Jones, MD, FRCP 15:50
Travel Grant Award Ceremony 16:00
Break Session VII: Gastric cancer Chairs: Cornelis J.H. van de Velde, MD, PhD
and Arnaud D. Roth, MD 16:30
What is optimal surgery for gastric cancer?
Cornelis J.H. van de Velde, MD, PhD 16:50
Should all patients be treated with adjuvant and/or neoadjuvant treatment?
Florian Lordick, MD, PhD 17:10
What is the reference cytotoxic regimen in advanced gastric cancer?
The US perspective: Daniel G. Haller, MD
The Asian perspective: Yung-Jue Bang, MD
The EU perspective: Andres Cervantes, MD, PhD 17:40
Presentation of selected abstract
Quality of life results from a phase III study of trastuzumab plus chemotherapy as first-line therapy in patients with HER2-positive advanced gastric and gastro-esophageal junction cancer
A. Ohtsu, et al., O-0011 17:50
What is the optimal algorithm for anti-HER2 targeted in gastric cancer?
Yung-Jue Bang, MD 18:00
Presentation of selected abstract AVAGAST: Randomized, double-blind, placebo-controlled, multicentre phase III study of capecitabine / cisplatin + bevacizumab or placebo as first-line therapy in patients with advanced
gastric cancer
A. Ohtsu, et al., O-0012 18:10
Which new targets are important in
gastric cancer?
Atsushi Ohtsu, MD, PhD 18:20
Adjourn
Friday, 2 July 2010
Session VIII: Meet the Expert
concurrent presentations
Parallel with Session IX: ESDO/IDCA Workshop, Session X:Presentation of selected abstracts, and Session XI: Clinical trials for GI oncologists 8:00
Carcinoma of unknown origin
Nicholas A. Pavlidis, MD, FACS
Level 1, Rooms 120-121 Supportive care: Management of emesis and anemia - guidelines
Mario Dicato, MD
Level 1, Rooms 122-123 Peritoneal metastases and mesothelioma
Brendan J. Moran, MCh, FRCSI
Level 1, Rooms 124-125 Gastrointestinal lymphoma
Bertrand Coiffier, MD
Level 1, Rooms 127-128 Session IX: ESDO/IDCA Workshop
Parallel with Session VIII: Meet the Expert concurrent presentations, Session X: Presentation of selected abstracts, and Session XI: Clinical trials for GI oncologists
Level 1, Rooms 129-130
Chairs: Guido N. J. Tytgat, MD, PhD and Philippe Rougier, MD, PhD 8:00
Updates on new European
screening guidelines
Lawrence von Karsa, MD 8:20
Barriers against screening – interventions to promote participation
Wolff Schmiegel, MD, PhD 8:40
Discussion
Guido N. J. Tytgat, MD, PhD, Philippe Rougier, MD, PhD, Wolff Schmiegel, MD, PhD, and Lawrence von Karsa, MD Session X: Selected abstracts II
Parallel with Session VIII: Meet the Expert concurrent presentations, Session IX: ESDO/IDSC Workshop, and Session XI: Clinical trials for
GI oncologists Chairs: Hans-Joachim Schmoll, MD, PhD and
Mario Dicato, MD 8:00
Presentation of selected abstracts Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in refractory metastatic colorectal cancer
S. Kopetz, et al., O-0013 Sunitinib plus 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) vs bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer (mCRC) - Interim results of a randomized, phase IIb study
J. Hecht, et al., O-0014 Randomized phase III study of panitumumab (pmab) with FOLFIRI compared to FOLFIRI alone as second-line treatment (tx) for metastatic colorectal cancer (mCRC): Secondary endpoint results
M. Peeters, et al., O-0015 Updated safety data from a randomized phase II trial of hedgehog pathway inhibitor gdc-0449 vs placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC)
J. Bendell, et al., O-0016 Subset analysis of 5-FU refractory patients from a randomized ph II study of perifosine + capecitabine (P-CAP) vs placebo + capecitabine (CAP) in patients with second or third line metastatic CRC
P. Hoff, et al., O-0017
Session XI: Clinical trials for GI oncologists:Trials and endpoints in GI cancer
Parallel with Session VIII: Meet the Expert concurrent presentations, Session IX: ESDO/IDCA Workshop and Session X: Presentation of selected abstracts
Level 1, Rooms 131-132
Chairs: Aimery de Gramont, MD and Eric Van Cutsem, MD, PhD 8:00
Is DFS, RR, or survival the best endpoint in colorectal cancer? Outcome of ARCAD working group
Aimery de Gramont, MD Which difference should we target?
Alberto Sobrero, MD Pharmacodynamic endpoints
Josep Tabernero, MD, PhD Is imaging with MRI useful for evaluation of activity?
Dow-Mu Koh, MD, MRCP, FRCR 9:30
Adjourn session Session XII: EONS Special Nurses’ Symposium: Nursing aspects on management of side effects of targeted agents
Parallel with Session XII: ESMO session: Focus on the young medical oncologist
Level 1, Rooms 120-121
Chairs: Anita Margulies, BSN, RN and Paz Fernandez-Ortega, RN, PhDc 9:00
Overview of the targeted therapies for GI cancers
Guy Berchem, MD and
Chris Verslype, MD, PhD 9:40
Optimizing the adherence for targeted therapies
Anita Margulies, BSN, RN 10:00
Management of the side effects
Liesbeth Lemmens, MSc, RN 10:20
Discussions 10:30
Break and Group 2 poster viewing (abstracts to be presented: clinical/basic gastric and clinical/basic other) Session XIII: ESMO session: Focus on the young medical oncologist
Parallel with session XII: EONS Special Nurses’ Symposium: Nursing aspects on management of side effects of targeted agents
Chairs: David J. Kerr, CBE, MA, MD, DSc, FRCP, FRCGP, FCanSci, FMedSci and Roberto Labianca, MD 9:00
Towards personalization in gastrointestinal cancer
David J. Kerr, CBE, MA, MD, DSc, FRCP, FRCGP, FCanSci, FMedSci 9:20
Unraveling the molecular signature of colon cancer – Have we made progress?
Sabine Tejpar, MD, PhD 9:40
Oncogenic mutations and targeted therapies in colon cancer - Have we made progress?
Alberto Bardelli, PhD 10:00
Keynote lecture 2: A new measure of treatment benefit in randomized trials, with applications to gastrointestinal cancer
Marc Buyse, ScD 10:30
Break and Group 2 poster viewing (abstracts to be presented: clinical/basic gastric and clinical/basic other) Session XIV: Multimodality therapy for rectal cancer
Chairs: Karin Haustermans, MD, PhD and Bengt Glimelius, MD, PhD 11:00
Imaging in rectal cancer: What is mandatory for optimal staging?
Geerard L. Beets, MD, PhD 11:20
Is sphincter saving surgery the goal in rectal cancer?
Debate
Pro
Andre D’Hoore, MD, PhD
Contra
Bernard Nordlinger, MD Discussion 11:40
Is local resection adequate for early rectal
tumor (TEMS)?
Alex Kartheuser, MD, MSc, PhD 11:50
Which neoadjuvant treatment in
rectal cancer?
Vincenzo Valentini, MD 12:05
A glimpse into the future of new radiation techniques for rectal cancer
Karin Haustermans, MD, PhD 12:20
How do we evaluate the quality of care in
rectal cancer?
Bruce D. Minsky, MD 12:35
Cases on rectal cancer
Selected by Karin Haustermans, MD, PhD and Bengt Glimelius, MD, PhD 13:00
Session adjourns 13:15
Concurrent luncheon symposia begin 14:45
Concurrent luncheon symposia adjourn Session XV: Highlights in oncology
Chair: Mario Dicato, MD 15:00
The increasing costs in oncology and the impact for the clinician
David Khayat, MD, PhD 15:30
Keynote lecture 3: The EGF receptor in cancer
Yosef Yarden, PhD 16:00
Keynote lecture 4: Angiogenesis inhibition in cancer
Peter Carmeliet, MD 16:30
Break Session XVI: Adjuvant treatment of colon cancer
Chairs: Axel Grothey, MD and Roberto Labianca, MD 17:00
Presentation of selected abstracts Molecular and clinical determinants of survival following relapse after treatment of stage II-III colon cancer (CC). Results of the translational study on the PETACC 3 - EORTC 40993 -SAKK 60-00 trial
A. Roth, et al., O-0018 Mutant KRAS and BRAF gene expression
profiles in colorectal cancer: Results of the translational study on the PETACC 3 - EORTC 40993 -SAKK 60-00 trial
S. Tejpar, et al., O-0019 Additional validation of a genomic signature (ColoPrint) for the risk stratification of stage II colon cancer patients
J. Tabernero, et al., O-0020 17:30
What is the role and impact of molecular markers on treatment decisions in the adjuvant setting?
Al B. Benson III, MD, FACP 17:50
How to treat a patient with stage III colon cancer in 2010
Hans-Joachim Schmoll, MD, PhD Session XVII: Poster discussion session 18:10
Poster discussion session on colon cancer
Axel Grothey, MD Poster discussion session on non-colorectal cancer
Roberto Labianca, MD 19:00
Adjourn
Saturday, 3 July 2010
Session XVIII: Screening and imaging of colon cancer
Chairs: Nadir Arber, MD, MSc, MHA and Nathalie Lassau, MD, PhD 8:15
Screening for colon cancer: Where are we now?
Nadir Arber, MD, MSc, MHA 8:35
Hereditary colon cancer syndromes
Hans F. Vasen, MD, PhD 8:55
Functional imaging for colon cancer The role of ultrasonography
Nathalie Lassau, MD, PhD The role of MRI
Dow-Mu Koh, MD, MRCP, FRCR The role of FDG-PET and of new PET tracers
Patrick Flamen, MD, PhD 9.40
Break and Group 3 poster viewing (abstracts
to be presented: clinical/basic colon and clinical/basic rectal) Session XIX: Metastatic colorectal cancer
Chairs: Eric Van Cutsem, MD, PhD and Alberto Sobrero, MD 10:10
What is the optimal treatment algorithm for metastatic CRC?
Alberto Sobrero, MD 10:30
Presentation of selected abstracts Macro/TTD phase III study of first-line XELOX plus BEV for 6 cycles followed by XELOX plus BEV or single agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer
E. Aranda, et al., O-0021 The addition of cetuximab to oxaliplatin-fluoropyrimidine chemotherapy in first-line advanced colorectal cancer in the MRC COIN trial: Identification of potentially responsive subsets of patients
T. Maughan, et al., O-0022 Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial
J. Douillard, et al., O-0023 The influence of KRAS and BRAF tumor mutation status on treatment outcome with cetuximab plus FOLFIRI: Final data from the CRYSTAL study
E. Van Cutsem, et al., O-0024 Intermittent vs continuous oxaliplatin-fluoropyrimidine chemotherapy in the MRC COIN trial in advanced colorectal cancer: Updated efficacy results, quality of life, and potential predictive factors
R. Adams, et al., O-0025 Final results from a randomized, double-blind, phase III study of sunitinib plus FOLFIRI vs placebo plus FOLFIRI in first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
A. Carrato, et al., O-0026 Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency abalation combined with chemotherapy for unresectable colorectal liver metastases
T. Ruers et al., Late breaking abstract 11:40
How long to treat metastatic CRC?
Eduardo Diaz-Rubio, MD 11:55
Molecular markers beyond KRAS for anti-EGFR and markers for
angiogenesis inhibitors
Fortunato Ciardiello, MD, PhD 12:15
New drugs on the horizon for CRC
John L. Marshall, MD 12:35
Discussion 12:45
Session adjourn 13:15
Concurrent luncheon symposia and ESO Cancer Observatory begin 14:45
Concurrent luncheon symposia and ESO Cancer Observatory adjourn Session XX: Colorectal cancer: Liver metastases
Chairs: Bernard Nordlinger, MD and Mario Dicato, MD 14:45
Presentation of ESSO Award winning abstract 14:55
Surgery for liver metastases: How far should the surgeon go?
Graeme J. Poston, MD 15:15
The multimodal treatment of liver metastases: Frequently asked questions
Bernard Nordlinger, MD 15:35
What is the optimal neo-adjuvant treatment for liver metastases?
Gunnar Folprecht, MD 15:55
Liver directed therapy - a critical analysis: Selective radiotherapy drug eluting beads or other
Philippe Rougier, MD, PhD Session XXI: Report on expert discussion 16:15
Presentation of outcome of expert discussion on the management of gastric cancer
Mario Dicato, MD and Eric Van Cutsem, MD, PhD 16:35
Adjourn |
